home :: clinical trials :: treatment trials :: clinical trial
CLINICAL TRIALS 

  CLINICAL TRIAL
 
Melanoma Clinical Trial
Reference
Unresectable Locally Advance or Stage IV: ECOG E2607

Title
DASATINIB IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR STAGE IV MUCOSAL, ACRAL AND VULVOVAGINAL MELANOMAS

Description

ELIGIBILITY
  • Histologically or cytologically confirmed melanoma of 1 of the following subtypes:

    • Acral melanoma (defined as occurring on the palms, soles, or subungual sites)

    • Melanoma arising from the vagina and/or vulva

    • Melanoma arising on other mucosal surface (not vagina or vulva)
  • Unresectable locally advanced or metastatic disease

  • c-KIT mutation identified by polymerase chain reaction (PCR) and sequencing

  • Measurable disease

  • No ocular melanoma

TREATMENT

Patients will receive dasatinib 70 mg to be taken by mouth twice daily. The medication is to be taken once in the morning and once in the evening with or without food. The cycle length of dasatinib is 21 days.

Additional Info
On the web: http://www.clinicaltrials.gov/ct2/search

back to Melanoma Clinical Trials 



©2004 MSCCOP & Mount Sinai Medical Center